Clinical Trials Cultivation DEA Programs 
Americans for Safe Access
JUNE 2, 2020
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
Cannabis Law Report
MARCH 30, 2022
Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. The full text of S. 253 is online here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
AUGUST 16, 2021
During the keynote session titled “Sue’n the DEA: The Story of a Cannabis Research Breakthrough,” Dr. Sisley—a pioneering medical cannabis researcher and volunteer medical director for more than 40 state cannabis licenses—will share her journey on navigating scientific and legal complexities of medical cannabis research. 25 from 11 a.m. –
Veriheal
APRIL 11, 2022
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. Drug Enforcement Agency (DEA). Fortunately, the U.S.
Canna Law Blog
JANUARY 3, 2023
Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”). It’s not like the FDA is unaware of the massive unregulated CBD market that already exists in the U.S.
CannaMD
AUGUST 8, 2020
Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. This new bill allows broad hemp cultivation.
SpeedWeed
MARCH 5, 2021
One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.
Expert insights. Personalized for you.
230 
Let's personalize your content